ASCO26: Jennifer Ligibel, MD, BWEL - Top-Institutions - MDSpire

ASCO26: Jennifer Ligibel, MD, BWEL

Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.

July 1, 2026

Dana-Farber

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology
#2

Harvard

Cambridge, MA
Key Differentiators
- Oncology
#3

Robert H. Lurie Comprehensive Cancer Center

Chicago, IL
Key Differentiators
- Oncology
#4

Weill Cornell Medical College

New York, NY
Key Differentiators
- Oncology
#5

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Oncology

Original Source(s)

Dana-Farber

ASCO26: Jennifer Ligibel, MD, BWEL

July 1, 2026

Related Content

Frontiers In Oncology

Homologous recombination pathway alterations in basal-like breast cancer

by Simon Aho, Boris Guyot, Véronique Maguer-Satta
June 18, 2026

Dana-Farber

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.